Raymond James Financial’s Haemonetics HAE Stock Holding History

Raymond James Financial’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.78M	Sell	137,978 -30,345	-18%	-$1.98M	﹤0.01%	2221
2025 Q4	$13.5M	Sell	168,323 -155,970	-48%	-$10.5M	﹤0.01%	1735
2025 Q3	$15.8M	Buy	324,293 +28,759	+10%	+$1.78M	0.01%	1583
2025 Q2	$22M	Sell	295,534 -95,322	-24%	-$6.31M	0.01%	1298
2025 Q1	$24.8M	Buy	390,856 +147,492	+61%	+$10M	0.01%	1147
2024 Q4	$19M	Buy	+243,364	New	+$19.5M	0.01%	1359

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Raymond James Financial's HAE Position: Q1 2026 in Review

Raymond James Financial reduced its Haemonetics (HAE) stake by 18% in Q1 2026, selling an estimated $1.98M and leaving 137,978 shares worth $7.78M. The position accounts for ﹤0.01% of the portfolio, ranked #2221.

Raymond James Financial first reported a position in HAE in Q4 2024 and has held it in 6 quarters since. The position peaked at $24.8M in Q1 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

Raymond James Financial held 137,978 shares of Haemonetics worth $7.78M as of Q1 2026.
Raymond James Financial sold 30,345 Haemonetics shares in Q1 2026, an estimated $1.98M.
Haemonetics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2221 holding.
Raymond James Financial first reported a position in Haemonetics in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Haemonetics position peaked at $24.8M in Q1 2025.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.